ARUNA BIO, INC.

Athens, GA · Biotech · Private

neural stem cell-derived extracellular vesicles (NSC EVs) for acute ischemic stroke treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · arunabio.com

Sector: Biotech
Headquarters: Athens, GA
Latest Form D: $13.3M, Aug 2019
Total capital: $27.7M

Federal grants: $5M; 2 awards · 2017–2019; Rank in peer group#162 of 514
Private capital raised: $19.8M; 3 Form D · last Aug 2019; 87 months since last filing
Federal contracts: $2.9M; 7 awards · Defense, Environmental Prot; Rank in Biotech#112 of 4373
Granted patents: 4; 6 pending · first 2021; Rank in peer group#85 of 514

Capital timeline

Latest events

Sep 2019Federal grantHealth and Human S · Phase II · Human Neural Cell Exosomes as a Therapeutic Treatment for Stroke$4.5M
Aug 2019Private capital raisedForm D · SEC · 3rd filing$13.3M
Jul 2018Private capital raisedForm D · SEC · 2nd filing$5.4M
Sep 2017Federal grantHealth and Human S · Phase I · Human Neural Cell Exosomes as a therapeutic treatment for stroke$500K
Jul 2017Federal contractEnvironmental Prot · Igf::ot::igf Aruna EPD13056 Task Order 3 Developmental Toxicity Models$121K
Aug 2016Private capital raisedForm D · SEC · 1st filing$1.2M
Feb 2016Federal contractEnvironmental Prot · Igf::ot::igf Developmental Toxicity Models For The Toxcast Program - Task Order 0002$186K

Show 5 earlier federal awards

Nov 2014Federal contractEnvironmental Prot · Igf::ot::igf Fund 2014 SBIR Phase II New Award - Aruna Biomedical, Inc. -developmental Neurotox Assay Using Scalable Neuron And Astrocytes In High Content Imaging$400K
Jun 2014Federal contractEnvironmental Prot · Igf::ot::igf Developmental Toxicity Models For The Toxcast Program$4K
May 2013Federal contractEnvironmental Prot · Igf::ot::igf Other Functions SBIR Phase I - Aruna Biomedical, Inc.$80K
Oct 2010Federal contractDefense · Research And Development In The Physical, Engineering, And Life Sciences (except Biotechnology)$1.1M
Dec 2009Federal contractDefense · Research And Development In The Physical, Engineering, And Life Sciences (except Biotechnology)$993K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

80months

from ARUNA BIO, INC.’s first federal award to its first private round.

First federal award · Dec 2009: Defense · $993K
First Form D · Aug 2016: $1.2M · 1st Form D
Awards before first raise: 6 awards

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#162 · top 32%
Granted patents#85 · top 17%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Steven SticeResearcherExecutive Officer, DirectorLinked by 4 patents
Al MedwarExecutive OfficerNamed in SEC Form D filings
Barry StoreyDirectorNamed in SEC Form D filings
C. William GriffinDirectorNamed in SEC Form D filings
Darren DeVoreDirectorNamed in SEC Form D filings
Harold IngallsDirectorNamed in SEC Form D filings

Show all 11 people

John ManganDirectorNamed in SEC Form D filings
Mark SirgoExecutive Officer, DirectorNamed in SEC Form D filings
Mason IrvingDirectorNamed in SEC Form D filings
Russell LindnerDirectorNamed in SEC Form D filings
Tracey SticeExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 4 granted of 10

May 14, 2026PendingExtracellular Vesicles For Treatment Of Amyotrophic Lateral SclerosisUSPTOApplication 19442667
May 12, 2026GrantedBinding Agents And Uses Thereof For Central Nervous System DeliveryUSPTOUS 12,622,978
Nov 12, 2024GrantedNeural Cell Extracellular VesiclesUSPTOUS 12,139,723

Show all 10 patent records

Extracellular Vesicles For Treatment Of Amyotrophic Lateral SclerosisMay 14, 2026 · Application 19442667Pending
Binding Agents And Uses Thereof For Central Nervous System DeliveryMay 12, 2026 · US 12,622,978Granted
Neural Cell Extracellular VesiclesNov 12, 2024 · US 12,139,723Granted
Neural Cell Extracellular VesiclesMay 28, 2024 · US 11,993,787Granted
Extracellular Vesicles And Uses Thereof For Antibody DeliveryDec 29, 2022 · Application 17735971Pending
Neural Cell Extracellular VesiclesSep 7, 2021 · US 11,111,475Granted
Binding Agents And Uses Thereof For Central Nervous System DeliveryApplication PCTUS2021029455Pending
Extracellular Vesicles And Uses Thereof For Antibody DeliveryApplication PCTUS2020058968Pending
Binding Agents And Uses Thereof For Central Nervous System DeliveryApplication 63015936Pending
Extracellular Vesicles And Uses Thereof For Antibody DeliveryApplication 62930178Pending

APOGEE BIOTECHNOLOGY CORPORATIONSimilar federal contract value in Biotech · $3M in contracts
AKINA, INC.Similar federal contract value in Biotech · $3M in contracts
ACTIVE MOTIF, INC.Similar federal contract value in Biotech · $2.9M in contracts
STC BIOLOGICS, INCSimilar federal contract value in Biotech · $2.8M in contracts
SYNVITROBIO, INC.Similar federal contract value in Biotech · $2.8M in contracts
EPIBONE, INC.Similar federal contract value in Biotech · $2.8M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.